-
Mashup Score: 14
Newsweek spoke to multiple cancer specialists about the concerning rise of cancers among people under 50.
Source: www.newsweek.comCategories: General Medicine NewsTweet
-
Mashup Score: 39Program Guide – ASCO Meeting Program Guide - 16 day(s) ago
Daneng Li City of Hope National Comprehensive Cancer Center, Duarte, CA Daneng Li, Sun Young Kim, Manish Patel, Hee Kyung Kim, Sunil Sharma, Sang Joon Shin, Jeeyun Lee, Sae-Won Han, Luke Chung, Songmao Zheng, Yan Li, Ping Xiao, Kristine She, Dana HuLowe, Jiangchun Xu, Stanley Frankel, Michael Chisamore, Peter Luo, Jiping Zha, Marwan Fakih City of Hope National Comprehensive Cancer Center, Duarte, CA, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Source: meetings.asco.orgCategories: General Medicine News, Oncologists2Tweet-
#ASCO25 Continuing with the #immunotherapy promise for the🆕subset of patients with NO active LIVER METASTASES ➖NLM MSS🧊colorectal cancer, see 👀 this👇🏽 ➡️ADG126 Masked CTLA4⛔️➕Pembro ORR ~ 2️⃣9️⃣%❗️Sustained📉. FRUQ 💊➕Immunotherapy arm. https://t.co/SUFt4ZSkDX @OncoAlert https://t.co/sjICYAhpZp
-
-
Mashup Score: 15Risk of bowel obstruction in patients with colon cancer responding to immunotherapy: an international case series - 17 day(s) ago
Immunotherapy is used routinely for treating deficient mismatch repair (dMMR) colon cancer (CC). This case series highlights an emerging safety issue, where patients develop bowel obstruction associated with immunotherapy response.
Source: www.esmoopen.comCategories: General Medicine NewsTweet-
@MyriamChalabi @OncoAlert @FASinicropeMD ⚠️Also, as we start using more neoadjuvant immunotherapy for MSI-High colon cancers, ☝🏽thing to be mindful of is that responses can be brisk/accelerated. Not uncommon to have this scenario of structure formation; ➡️bowel obstruction. #ASCO25 @OncoAlert https://t.co/YjdR13CMz7 https://t.co/r2cNSD5cgH
-
-
Mashup Score: 5
Should biologics be the initial treatment for immune checkpoint inhibitor colitis?
Source: ascopubs.orgCategories: General Medicine NewsTweet-
@OncoAlert @mgfakih @isliquidbiopsy @FightCRC @CCAlliance @colontown Important piece @JCO_ASCO that I have found of extreme value in mitigating/stopping🛑immune-related serious adverse events the moment you realize it’s happening. 💉TNFa⛔️ ✅Steroid sparing. 💡Time to adapt. We overuse steroids❌. @OncoAlert #ASCO25 🔗https://t.co/vub6gYA7as https://t.co/lkDvBn5r7b
-
-
Mashup Score: 4
Pashtoon Kasi: ASCO25 starts with ctDNA and colorectal cancer / ASCO 2025, ASCO25, cancer, City of Hope, colorectal cancer, ctDNA and colorectal cancer,
Source: oncodaily.comCategories: General Medicine News, Oncologists2Tweet-
RT @OncoDailyGI: ASCO25 starts with ctDNA and colorectal cancer - @pashtoonkasi @ASCO https://t.co/HNOlgFcHfH #ASCO2025 #ASCO25 #Cance…
-
-
Mashup Score: 4Pashtoon Kasi: The immunotherapy story evolves for patients with MSS colorectal cancer - OncoDaily - 18 day(s) ago
Pashtoon Kasi: The immunotherapy story evolves for patients with MSS colorectal cancer / ASCO 2025, cancer, City of Hope, MSS colorectal cancer, OncoDaily,
Source: oncodaily.comCategories: General Medicine News, Oncologists2Tweet-
RT @OncoDailyIO: The immunotherapy story evolves for patients with MSS colorectal cancer - @pashtoonkasi https://t.co/P0S5JsMBGB #ASCO2…
-
-
Mashup Score: 25Program Guide – ASCO Meeting Program Guide - 18 day(s) ago
Gertjan Rasschaert Gastrointestinal Oncology Department, University Hospitals Leuven, Leuven, Belgium Gertjan Rasschaert, Ana Mendizabal-Sasieta, Allyson Peddle, Marta Grzelak, Robin Govaerts, Joseph Grossman, Marta Soto, Qian Wu, Benny Johnson, Filip Van Herpe, Steven O’Day, Dhan Chand, Sabine Tejpar, Holger Heyn Gastrointestinal Oncology Department, University Hosp itals Leuven, Leuven, Belgium, Omniscope Inc., Barcelona, CA, Spain, Laboratory for Digestive Oncology, KU Leuven, Leuven, Belgium, Agenus
Source: meetings.asco.orgCategories: General Medicine News, Oncologists2Tweet-
#ASCO25 This is 🆒👇🏽 The T-Cell Dynamics🔴🟠🟡& activity score🟢🔵🟣in patients with colorectal cancer getting🤖BOT/BAL➖Botensilimab CTLA4⛔️. We noticed this in my #NEST🪺1/2 study. 💡Underestimate how QUICKLY ✅immunotherapy can work📉. https://t.co/IjpOaJ3O7e @OncoAlert https://t.co/iCkJ4qWnb6
-
-
Mashup Score: 57Program Guide – ASCO Meeting Program Guide - 18 day(s) ago
Marwan Fakih City of Hope Comprehensive Cancer Center, Duarte, CA Marwan Fakih, Nicholas DeVito, Aparna Parikh, Tanios Bekaii-Saab, Hao Xie, Sandra Algaze, Alexander Spira, J eremy Jones, Cesar Perez, Andrae Vandross, Alberto Bessudo, John Knecht, Ekta Patel, Damiano Fantini, Scott McConnell, Myra Popejoy, Bruce Dezube, Diwakar Davar, Joel Hecht City of Hope Comprehensive Cancer Center, Duarte, CA, Duke University Medical Center, Duke Cancer Institute, Durham, NC, Massachusetts General Hospital, Boston,
Source: meetings.asco.orgCategories: General Medicine NewsTweet-
#ASCO25👏🏽Encouraging signals as the #immunotherapy story evolves for patients with microsatellite stable (MSS)🧊colorectal cancer. ✅Vilastobart (XTX101)➡️Tumor-activated Fc-enhanced CTLA-4⛔️➕PD-L1⛔️showing deep/durable responses📉 “Cures”. 🔗https://t.co/yroid0g5wO @OncoAlert https://t.co/CVgSXTunHr
-
-
Mashup Score: 32
Location Hilton Chicago 720 South Michigan Avenue Chicago, Illinois Phone: (312) 922-4400 Program Schedule — Central Time 6:00 PM – 6:30 PM — Registration and Dinner 6:30 PM – 8:30 PM — Educational Meeting Meeting Room Continental Room C (Lobby Level) There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited. Faculty Andrea Cercek, MD Section Head, Colorectal Cancer Co-Director, Center for Young Onset Colorectal and Gastrointestin
Source: m.researchtopractice.comCategories: General Medicine NewsTweet-
#ASCO25 Tonight. No registration fees. Remember the @ASCO ancillary CME events. 🎙️@DrNeilLove Great lineup of speakers & talks. Both as a student and a participant, I’ve really enjoyed this particular event. Come; bring friends along. @OncoAlert 🔗 https://t.co/ik2KfDs8QY https://t.co/hJVqqmoUbC
-
-
Mashup Score: 15
First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer, an…
Source: www.nejm.orgCategories: General Medicine NewsTweet-
@OncoAlert Concurrent publication @NEJM! #ASCO25 1st 🎤drop. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. @OncoAlert https://t.co/d0S5S2XzPa
-
📰🗞️@Newsweek 🎙️Discussed the troubling rise of #cancer 📈in young adults. Genetics🧬is not responsible for most of the cases. Obesity too doesn’t explain the full picture since a lot of our patients are very active/healthy. ✍️@LucyNotaranton2 🔗https://t.co/WZgEn3mGT3 https://t.co/7kUNcEYCXI